HomeCompareADAPY vs GIS

ADAPY vs GIS: Dividend Comparison 2026

ADAPY yields 17391.30% · GIS yields 6.55%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ADAPY wins by $13116176655014998016.00M in total portfolio value
10 years
ADAPY
ADAPY
● Live price
17391.30%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$13116176655014998016.00M
Annual income
$12,969,477,336,575,606,000,000,000.00
Full ADAPY calculator →
GIS
GIS
● Live price
6.55%
Share price
$37.11
Annual div
$2.43
5Y div CAGR
22.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$79.2K
Annual income
$16,311.42
Full GIS calculator →

Portfolio growth — ADAPY vs GIS

📍 ADAPY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodADAPYGIS
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ADAPY + GIS cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ADAPY pays
GIS pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ADAPY
Annual income on $10K today (after 15% tax)
$1,478,260.87/yr
After 10yr DRIP, annual income (after tax)
$11,024,055,736,089,265,000,000,000.00/yr
GIS
Annual income on $10K today (after 15% tax)
$556.59/yr
After 10yr DRIP, annual income (after tax)
$13,864.71/yr
At 15% tax rate, ADAPY beats the other by $11,024,055,736,089,265,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ADAPY + GIS for your $10,000?

ADAPY: 50%GIS: 50%
100% GIS50/50100% ADAPY
Portfolio after 10yr
$6558088327507499008.00M
Annual income
$6,484,738,668,287,803,000,000,000.00/yr
Blended yield
98.88%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ADAPY right now

ADAPY
Analyst Ratings
9
Buy
4
Hold
3
Sell
Consensus: Buy
Price Target
$2.83
+24508.7% upside vs current
Range: $1.00 — $4.00
Altman Z
-15.9
Piotroski
0/9
GIS
Analyst Ratings
9
Buy
19
Hold
6
Sell
Consensus: Hold
Price Target
$47.42
+27.8% upside vs current
Range: $35.00 — $63.00
Altman Z
2.2
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ADAPY buys
0
GIS buys
0
No recent congressional trades found for ADAPY or GIS in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricADAPYGIS
Forward yield17391.30%6.55%
Annual dividend / share$2.00$2.43
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%22.8%
Portfolio after 10y$13116176655014998016.00M$79.2K
Annual income after 10y$12,969,477,336,575,606,000,000,000.00$16,311.42
Total dividends collected$13106484814212466688.00M$51.1K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyHold
Analyst price target$2.83$47.42

Year-by-year: ADAPY vs GIS ($10,000, DRIP)

YearADAPY PortfolioADAPY Income/yrGIS PortfolioGIS Income/yrGap
1← crossover$1,749,830$1,739,130.43$11,504$804.11+$1.74MADAPY
2$286,281,979$284,409,660.27$13,371$1,061.65+$286.27MADAPY
3$43,793,237,807$43,486,916,089.97$15,723$1,416.15+$43793.22MADAPY
4$6,263,959,119,982$6,217,100,355,528.48$18,735$1,911.16+$6263959.10MADAPY
5$837,788,422,535,934$831,085,986,277,552.80$22,660$2,613.51+$837788422.51MADAPY
6$104,780,184,325,077,740$103,883,750,712,964,290.00$27,874$3,627.81+$104780184325.05MADAPY
7$12,254,629,759,849,812,000$12,142,514,962,621,979,000.00$34,947$5,121.52+$12254629759849.78MADAPY
8$1,340,341,587,727,856,400,000$1,327,229,133,884,817,100,000.00$44,762$7,369.21+$1340341587727856.50MADAPY
9$137,102,166,765,785,570,000,000$135,668,001,266,916,780,000,000.00$58,728$10,832.80+$137102166765785568.00MADAPY
10$13,116,176,655,014,997,000,000,000$12,969,477,336,575,606,000,000,000.00$79,151$16,311.42+$13116176655014998016.00MADAPY

ADAPY vs GIS: Complete Analysis 2026

ADAPYStock

Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops TECELRA ((famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatment synovial sarcoma and myxoid liposarcoma; and ADP-5701, which is in Phase 1 clinical trial for the treatment of head and neck cancer. The company also focuses on the development of T-cell therapies directed to PRAME (ADP-600) and CD70 (ADP-520). It has strategic collaboration with Galapagos to clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel produced on Galapagos' decentralized manufacturing platform (ADP-5701) in patients with head and neck cancer; collaboration and license agreement with Noile-Immune Biotech, Inc. and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Full ADAPY Calculator →

GISConsumer Staples

General Mills, Inc. manufactures and markets branded consumer foods worldwide. The company operates in five segments: North America Retail; Convenience Stores & Foodservice; Europe & Australia; Asia & Latin America; and Pet. It offers ready-to-eat cereals, refrigerated yogurt, soup, meal kits, refrigerated and frozen dough products, dessert and baking mixes, bakery flour, frozen pizza and pizza snacks, snack bars, fruit and salty snacks, ice cream, nutrition bars, wellness beverages, and savory and grain snacks, as well as various organic products, including frozen and shelf-stable vegetables. It also supplies branded and unbranded food products to the North American foodservice and commercial baking industries; and manufactures and markets pet food products, including dog and cat food. The company markets its products under the Annie's, Betty Crocker, Bisquick, Blue Buffalo, Blue Basics, Blue Freedom, Bugles, Cascadian Farm, Cheerios, Chex, Cinnamon Toast Crunch, Cocoa Puffs, Cookie Crisp, EPIC, Fiber One, Food Should Taste Good, Fruit by the Foot, Fruit Gushers, Fruit Roll-Ups, Gardetto's, Go-Gurt, Gold Medal, Golden Grahams, Häagen-Dazs, Helpers, Jus-Rol, Kitano, Kix, Lärabar, Latina, Liberté, Lucky Charms, Muir Glen, Nature Valley, Oatmeal Crisp, Old El Paso, Oui, Pillsbury, Progresso, Raisin Nut Bran, Total, Totino's, Trix, Wanchai Ferry, Wheaties, Wilderness, Yoki, and Yoplait trademarks. It sells its products directly, as well as through broker and distribution arrangements to grocery stores, mass merchandisers, membership stores, natural food chains, e-commerce retailers, commercial and noncommercial foodservice distributors and operators, restaurants, convenience stores, and pet specialty stores, as well as drug, dollar, and discount chains. The company operates 466 leased and 392 franchise ice cream parlors. General Mills, Inc. was founded in 1866 and is headquartered in Minneapolis, Minnesota.

Full GIS Calculator →
📬

Get this ADAPY vs GIS comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ADAPY vs SCHDADAPY vs JEPIADAPY vs OADAPY vs KOADAPY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.